Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
129 participants
INTERVENTIONAL
2007-12-31
2008-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Brimonidine Purite 0.15% Versus Dorzolamide 2% Used as Adjunctive Therapy to Latanoprost
NCT00348400
A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension
NCT00314171
A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension
NCT00326092
A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension
NCT00333125
Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-02-41
NCT00047528
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AL-3862+timolol, then COSOPT
AL-3862+timolol ophthalmic suspension, 1 drop in both eyes, followed by dorzolamide+timolol ophthalmic solution,1 drop in both eyes, 1 day later.
AL-3862+timolol ophthalmic suspension
Dorzolamide+timolol ophthalmic solution
COSOPT, then AL-3862+timolol
Dorzolamide+timolol ophthalmic solution, 1 drop in both eyes, followed by AL-3862+timolol ophthalmic suspension, 1 drop in both eyes, 1 day later.
AL-3862+timolol ophthalmic suspension
Dorzolamide+timolol ophthalmic solution
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AL-3862+timolol ophthalmic suspension
Dorzolamide+timolol ophthalmic solution
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of glaucoma or ocular hypertension;
* On a stable regimen of any intraocular pressure (IOP) lowering medication (mono-therapy);
* IOP for which, in the opinion of the investigator, participation in the study does not present a risk to ocular health;
Exclusion Criteria
* Pregnant, nursing, or not using highly effective birth control methods;
* Use of oral or topical corticosteroids within 30 days of the Screening Visit and during the course of the study;
* History of bronchial asthma or severe chronic obstructive pulmonary disease;
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alcon Research
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C-07-47
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.